Clinical trial NCT00414115: National Active Surveillance Network and Pharmacogenomics of Adverse Drug Reactions in Children
Official title: Canadian Pharmacogenomics Network for Drug Safety
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Adverse Drug Reaction (ADR)
Keywords: Observational controlled study
Genomic biomarkers
Adverse drug reaction
In children OR adults
Lead sponsor: University of British Columbia
Sponsor class: OTHER
Collaborators: name: Genome Canada
name: Genome British Columbia
name: Child and Family Research Institute
name: Western University, Canada
name: Provincial Health Services Authority
name: Health Canada
name: Canada Gene Cure
name: Eli Lilly and Company
name: Pfizer
name: Merck Sharp & Dohme LLC
name: Canadian Society of Clinical Pharmacology
name: Canadian Institutes of Health Research (CIHR)
name: Canada Foundation for Innovation
name: British Columbia Clinical Genomics Network
First posted: 2006-12-21
Enrollment: 7000
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: OTHER
Sampling method: PROBABILITY_SAMPLE
Study population: Children under 19 years who have taken drugs and adults to replicate findings in children

Brief summary: The purpose of the study is (1) to identify and collect samples from children and adults who take drugs and have adverse drug reactions AND children and adults who take drugs and do not experience any adverse drug effects; (2) to determine if genetic differences between the two groups contribute to causing the adverse drug reactions; and (3) to develop patient specific drug dosing guidelines to prevent future adverse drug reactions. We also wish to compare the use of prescription drugs, medical and hospital services and vital statistics between BC participants who experience adverse drug reactions and those who do not.

Study hypothesis: Genetic differences may contribute to patients' response to drugs and may be responsible for adverse drug reactions.

Detailed description: CPNDS will identify ADR predictive markers by comparing DNA and plasma samples from patients that suffer ADRs with samples from control populations that are stratified by medication type and age. The GATC will obtain its clinical material for ADR patients mainly, from hospital-based active surveillance network across Canada's major hospitals.

1. CPNDS will examine known SNPs in candidate genes related to the ADR (i.e. drug metabolism genes, drug transporter genes, drug target genes, and other disease-specific genes or genes related to the physiological pathway of the ADR.) 2. CPNDS will discover novel ADR predictive SNPs and mutations by sequencing DNA samples from our patient cohorts. CPNDS will also genotype and sequence DNA samples from populations of controls that received the same drugs, but did not suffer ADRs; and a second population of control patients who represent a random sample of the population of known ethnic backgrounds.

Novel ADR predictive SNPs and mutations will be functionally validated by pharmacokinetic approaches applied to time course analysis of drug concentrations for each specific genotype. Pharmacokinetic studies will also be used to determine the drug concentration in patients to characterize possible mechanisms of the ADR, translating into rational approaches to the choice of candidate genes to be examined in the genomic analyses.

The cost-effectiveness of an ADR screening program for the prevention of ADRs in children and adults will be calculated in detailed health-economic studies.

Eligibility criteria: Inclusion Criteria:

* Children under 19 years who have taken drugs.
* Biological parents of children who have had an ADR.
* Patients/parents who speak and understand English (except in Quebec).
* Adults (for validation of findings in children)

Primary outcomes:
measure: Determine the role of genetic and clinical factors in adverse drug reactions to develop risk mitigation strategies.
timeFrame: December 2018
Secondary outcomes:
Other outcomes:
Locations:
city: Vancouver
country: Canada
facility: Children's and Women's Health Centre of British Columbia
state: British Columbia
Study officials:
affiliation: University of British Columbia
name: Bruce Carleton, Pharm. D.
role: PRINCIPAL_INVESTIGATOR
affiliation: University of British Columbia
name: Michael Hayden, MD, Ph.D
role: PRINCIPAL_INVESTIGATOR
References:
citation: Carleton B, Poole R, Smith M, Leeder J, Ghannadan R, Ross C, Phillips M, Hayden M. Adverse drug reaction active surveillance: developing a national network in Canada's children's hospitals. Pharmacoepidemiol Drug Saf. 2009 Aug;18(8):713-21. doi: 10.1002/pds.1772.